At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 114 enrolled
Drug / intervention
CVX-096biological
Likely dose
CVX-096 0.1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Escalating Subcutaneous Doses Of Cvx-096 In Type 2 Diabetic Adult Subjects
In Brief
A Phase 1 clinical trial evaluating CVX-096 for Diabetes Mellitus, Type 2. Completed, enrolled 114 participants across 2 sites.
Detailed Summary
The purpose of this study is to determine safety and tolerability of CVX-096 in adult, type 2 diabetic patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2008
First PostedApr 2009
Primary CompletionJun 2011
TodayJul 2026
First PostedApr 23, 2009
Enrollment StartOct 1, 2008
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 17.2 years ago
Interventions
CVX-096biological
Subcutaneous administration of CVX-096 with doses ranging from 0.1 mg up to a maximum of 36 mg